Association of Systolic Blood Pressure and Pulse Pressure with Microalbuminuria in Treatment-naïve Hypertensive Patients

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2019 Jul 31

PMID 31360177

Citations 1

Authors

Nianjin Xie

Xida Li

Qi Zhong

Dan Zhou

Anping Cai

Ying Zhang

Yingling Zhou

Yingqing Feng

Affiliations

Soon will be listed here.

Abstract

Introduction: To investigate the association between blood pressure components and microalbuminuria (MAU) in newly diagnosed and treatment-naïve hypertensive patients.

Material And Methods: A total of 1858 newly diagnosed and treatment-naïve hypertensive patients were enrolled. Based on 24 h urine albumin concentration, all patients were divided into MAU and normo-albuminuria groups. The associations between blood pressure (BP) components, namely systolic/diastolic BP (SBP/DBP) and pulse pressure (PP) and MAU, as well as the sensitivity and specificity of each BP component in predicting MAU, were evaluated.

Results: Compared to the normo-albuminuria group, patients in the MAU group were older and had significantly higher SBP and PP ( < 0.05). Serum levels of fasting blood glucose, total protein and creatinine were significantly higher in the MAU group ( < 0.05). 24-hour urine albumin excretion was significantly higher in the MAU group than the normo-albuminuria group (182.5 ±156.5 mg vs. 17.6 ±7.1 mg, < 0.001). Logistic regression analyses revealed that SBP and PP were significantly associated with MAU, with an odds ratio (OR) of 1.010 (95% confidence interval (CI): 1.005-1.016, < 0.001) in SBP and OR of 1.009 (95% CI: 1.003-1.015, = 0.003) in PP. The receiver operating characteristic curve showed that the area under the curve for SBP to predict MAU was 0.541 ±0.013, and PP was 0.536 ±0.013. The difference in predicting MAU by SBP or PP was non-significant.

Conclusions: In newly diagnosed and treatment-naïve hypertensive patients, increased SBP and PP were independently associated with MAU.

Citing Articles

High prevalence of albuminuria among adult males living with HIV in Botswana.

Mosepele M, Ponatshego P, Molebatsi K, Williams C, Mokgatlhe L, Lockman S Sci Rep. 2024; 14(1):14432.

PMID: 38910157 PMC: 11194263. DOI: 10.1038/s41598-024-65099-w.

References

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

Kottke T, Stroebel R, Hoffman R . JNC 7--it's more than high blood pressure. JAMA. 2003; 289(19):2573-5. DOI: 10.1001/jama.289.19.2573. View

Cottone S, Mule G, Nardi E, Lorito M, Guarneri M, Arsena R . Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens. 2006; 21(2):167-72. DOI: 10.1038/sj.jhh.1002109. View

Urushihara M, Kobori H . Angiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease. Int J Clin Med. 2012; 2(1):378-387. PMC: 3255085. DOI: 10.4236/ijcm.2011.24064. View

Jesic M, Sajic S, Jesic M, Kostic M, Peco-Antic A, Vujnovic Z . Microalbuminuria in relation to metabolic control and blood pressure in adolescents with type 1 diabetes. Arch Med Sci. 2012; 7(6):1037-41. PMC: 3264997. DOI: 10.5114/aoms.2011.26617. View

Franco M, Tapia E, Bautista R, Pacheco U, Santamaria J, Quiroz Y . Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. Am J Physiol Renal Physiol. 2013; 304(7):F982-90. PMC: 3625854. DOI: 10.1152/ajprenal.00463.2012. View

Kusunoki H, Taniyama Y, Rakugi H, Morishita R . Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptorγ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc. 2013; 2(2):e000103. PMC: 3647265. DOI: 10.1161/JAHA.113.000103. View

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

Liu X, Wang K, Wang L, Tsilimingras D . Microalbuminuria, macroalbuminuria and uncontrolled blood pressure among diagnosed hypertensive patients: the aspect of racial disparity in the NHANES study. Hypertens Res. 2013; 36(12):1100-6. DOI: 10.1038/hr.2013.87. View

10.

Allen N, Siddique J, Wilkins J, Shay C, Lewis C, Goff D . Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014; 311(5):490-7. PMC: 4122296. DOI: 10.1001/jama.2013.285122. View

11.

Banach M, Serban C, Aronow W, Rysz J, Dragan S, Lerma E . Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014; 46(5):947-61. PMC: 4012155. DOI: 10.1007/s11255-014-0657-6. View

12.

Khangura K, Eirin A, Kane G, Misra S, Textor S, Lerman A . Extrarenal atherosclerotic disease blunts renal recovery in patients with renovascular hypertension. J Hypertens. 2014; 32(6):1300-6. PMC: 4016960. DOI: 10.1097/HJH.0000000000000160. View

13.

Bansal N, McCulloch C, Rahman M, Kusek J, Anderson A, Xie D . Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension. 2014; 65(1):93-100. PMC: 4268143. DOI: 10.1161/HYPERTENSIONAHA.114.04334. View

14.

Ryoo J, Chun H, Lee H, Suh E, Choi J, Kim M . Clinical associations between metabolic syndrome and the development of microalbuminuria in Korean men. Diabetes Res Clin Pract. 2015; 107(3):407-14. DOI: 10.1016/j.diabres.2014.12.005. View

15.

Xanthakis V, Sung J, Samdarshi T, Hill A, Musani S, Sims M . Relations between subclinical disease markers and type 2 diabetes, metabolic syndrome, and incident cardiovascular disease: the Jackson Heart Study. Diabetes Care. 2015; 38(6):1082-8. PMC: 4439537. DOI: 10.2337/dc14-2460. View

16.

Thieme K, Oliveira-Souza M . Renal hemodynamic and morphological changes after 7 and 28 days of leptin treatment: the participation of angiotensin II via the AT1 receptor. PLoS One. 2015; 10(3):e0122265. PMC: 4368722. DOI: 10.1371/journal.pone.0122265. View

17.

Yano Y, Fujimoto S, Kramer H, Sato Y, Konta T, Iseki K . Long-Term Blood Pressure Variability, New-Onset Diabetes Mellitus, and New-Onset Chronic Kidney Disease in the Japanese General Population. Hypertension. 2015; 66(1):30-6. DOI: 10.1161/HYPERTENSIONAHA.115.05472. View

18.

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T . Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015; 387(10017):435-43. DOI: 10.1016/S0140-6736(15)00805-3. View

19.

Ettehad D, Emdin C, Kiran A, Anderson S, Callender T, Emberson J . Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387(10022):957-967. DOI: 10.1016/S0140-6736(15)01225-8. View

20.

Lee E, Oh H, Park J, Han S, Ryu D, Kang S . The Incidence of Cardiovascular Events Is Comparable Between Normoalbuminuric and Albuminuric Diabetic Patients With Chronic Kidney Disease. Medicine (Baltimore). 2016; 95(15):e3175. PMC: 4839801. DOI: 10.1097/MD.0000000000003175. View